Ovarian Neoplasm

Oncology
2
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
1 program
1
Nab-paclitaxel 80 mg/m^2Phase 31 trial
Active Trials
NCT05257408Active Not Recruiting381Est. Mar 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
KU-0059436Phase 25 trials
Active Trials
NCT00572364Completed18Est. Jun 2009
NCT00516438Completed48Est. Nov 2009
NCT00494442Completed58Est. Jul 2017
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Corcept TherapeuticsNab-paclitaxel 80 mg/m^2
AstraZenecaKU-0059436
AstraZenecaKU-0059436
AstraZenecaKU-0059436
AstraZenecaKU-0059436
AstraZenecaKU-0059436

Clinical Trials (6)

Total enrollment: 643 patients across 6 trials

NCT05257408Corcept TherapeuticsNab-paclitaxel 80 mg/m^2

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Start: Jun 2022Est. completion: Mar 2026381 patients
Phase 3Active Not Recruiting
NCT00494442AstraZenecaKU-0059436

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Start: Jun 2007Est. completion: Jul 201758 patients
Phase 2Completed
NCT00572364AstraZenecaKU-0059436

Open Label, Dose Escalation Phase I Study of AZD2281

Start: Nov 2007Est. completion: Jun 200918 patients
Phase 1Completed
NCT00516438AstraZenecaKU-0059436

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Start: Jul 2007Est. completion: Nov 200948 patients
Phase 1Completed
NCT00516802AstraZenecaKU-0059436

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Start: Jan 2007Est. completion: Jan 200940 patients
Phase 1Completed
NCT00516373AstraZenecaKU-0059436

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Start: Jul 2005Est. completion: Apr 202398 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
12m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)